| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Cell based cancer vaccines: Regulatory and commercial development
|
Copier, John
|
|
2007
|
25 |
S2 |
p. B35-B46
nvt p.
|
article
|
| 2 |
Clinical proteomics: Discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—A prostate cancer perspective
|
Matharoo-Ball, Balwir
|
|
2007
|
25 |
S2 |
p. B110-B121
nvt p.
|
article
|
| 3 |
Dendritic cells for active immunotherapy: Optimizing design and manufacture in order to develop commercially and clinically viable products
|
Nicolette, C.A.
|
|
2007
|
25 |
S2 |
p. B47-B60
nvt p.
|
article
|
| 4 |
Editorial Board
|
|
|
2007
|
25 |
S2 |
p. CO2-
1 p.
|
article
|
| 5 |
Enhancing cancer vaccines with immunomodulators
|
Berinstein, Neil L.
|
|
2007
|
25 |
S2 |
p. B72-B88
nvt p.
|
article
|
| 6 |
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
|
Gulley, James L.
|
|
2007
|
25 |
S2 |
p. B89-B96
nvt p.
|
article
|
| 7 |
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
|
Brichard, Vincent G.
|
|
2007
|
25 |
S2 |
p. B61-B71
nvt p.
|
article
|
| 8 |
Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)
|
Finke, Lothar H.
|
|
2007
|
25 |
S2 |
p. B97-B109
nvt p.
|
article
|
| 9 |
Perspectives on the development of a therapeutic HER-2 cancer vaccine
|
Renard, Valéry
|
|
2007
|
25 |
S2 |
p. B17-B23
nvt p.
|
article
|
| 10 |
Plasmid DNA and viral vector-based vaccines for the treatment of cancer
|
Anderson, Richard J.
|
|
2007
|
25 |
S2 |
p. B24-B34
nvt p.
|
article
|
| 11 |
Therapeutic cancer vaccines
|
Ward, Stephen
|
|
2007
|
25 |
S2 |
p. B1-B3
nvt p.
|
article
|
| 12 |
Vaccine therapy for melanoma: Current status and future directions
|
Terando, Alicia M.
|
|
2007
|
25 |
S2 |
p. B4-B16
nvt p.
|
article
|
Journal description